A Phase I trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of VIT-2763 on iron metabolism and blood levels when administered in single and multiple doses in healthy volunteers

Trial Profile

A Phase I trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of VIT-2763 on iron metabolism and blood levels when administered in single and multiple doses in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs VIT-2763 (Primary)
  • Indications Anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Feb 2018 New trial record
    • 08 Feb 2018 According to a Vifor Pharma media release, a Clinical Trial Application (CTA) for this trial was submitted in November 2017 and approved on 19 December 2017
    • 08 Feb 2018 According to a Vifor Pharma media release, this study will initiate at the beginning of March 2018 and first results from the study are expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top